recurrent respiratory papillomatosishormone-resistant metastatic prostate cancerR/M HPV16+ head and neck cancerzopapogene imadenovecFood and Drug Administrationsipuleucel-TPD-1 blocker
…id phosphatase; and zopapogene imadenovec, approved in 2025 for recurrent respiratory papillomatosis, a rare, non-malignant but often invalidating disease caused by…